On July 31, 2026 Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), ("Amplia" or the "Company"), reported that a scientific manuscript detailing extensive preclinical studies of narmafotinib in pancreatic cancer has been made publicly available on the biology preprint server bioRxiv and can be accessed via this link.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The manuscript describes research conducted by Professor Paul Timpson and colleagues at the Garvan Institute of Medical Research, Sydney, and provides further insight into the multiple mechanisms through which narmafotinib may act to improve outcomes in pancreatic cancer.
Key findings reported in the manuscript include:
*Reduction of tumour fibrosis, a hallmark of pancreatic cancer that contributes to treatment resistance and impaired drug delivery;
*Enhanced anti-tumour activity when combined with chemotherapy across multiple preclinical pancreatic cancer models;
*Reduced cancer dissemination and metastatic spread in a model of metastatic pancreatic cancer; and
*Downregulation of multiple genes associated with chemotherapy resistance, further supporting the biological rationale for combining narmafotinib with chemotherapy and other drugs
Dr Chris Burns, CEO and Managing Director of Amplia commented: "We are delighted that the extensive research conducted by Professor Timpson’s team at the Garvan Institute over recent years is now being shared with the broader scientific community. Importantly, these studies strengthen the scientific rationale for the clinical development of narmafotinib, and provides further insight into the multifaceted mechanisms through which narmafotinib can act in the treatment of this devastating disease."
The publication represents one of the most comprehensive preclinical evaluations of narmafotinib undertaken to date and further supports Amplia’s ongoing clinical development program in pancreatic cancer.
This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.
(Press release, Amplia Therapeutics, JUL 31, 2026, View Source [SID1234669584])